Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 123

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 123
---
 Kaken and its representatives any non-public information concerning Aadi and its subsidiaries that is made available to any such person or group or their respective representatives and that was not previously made available to Kaken. Aadi’s board of directors may only take the foregoing actions if Aadi’s board of directors has determined in good faith (after consultation with its financial advisor and outside legal counsel) that (1) such acquisition proposal either constitutes a Superior Proposal or is reasonably likely to lead a Superior Proposal, and (2) the failure to take such actions could reasonably be expected to be inconsistent with its fiduciary duties. From the date of the Divestiture Agreement until the earlier to occur of the completion of the Divestiture and the termination of the Divestiture Agreement, Aadi has agreed that it will - 82 -

promptly (and, in any event, within 24 hours from the receipt thereof) notify Kaken in writing if any acquisition inquiry or acquisition proposal is, to the knowledge of Aadi Sub (which, for this purpose, will be deemed to include each member of Aadi’s board of directors and will not be deemed to be only as of the date of the Divestiture Agreement), received by, or any discussions or negotiations are sought to be initiated or continued with, Aadi, Aadi Sub or any of their respective representatives with respect to an acquisition inquiry or acquisition proposal. Such notice must include (1) the identity of the person or group making such acquisition inquiry or acquisition proposal, and (2) a summary of the material terms and conditions of such acquisition inquiry or acquisition proposal and, if in writing, a copy thereof. Thereafter, Aadi or Aadi Sub must keep Kaken reasonably informed, on a prompt basis, of the status and terms of any such acquisition inquiry or acquisition proposal (including any amendments or supplements thereto) and the status of any such discussions or negotiations. For purposes of this proxy statement and the Divestiture Agreement, “Superior Proposal” means a bona fide written acquisition proposal from any person other than Kaken or any of its affiliates that did not result from any material breach of Aadi’s, Aadi Sub’s, or their respective representatives’ obligations with respect to the solicitation and receipt of Alternative Acquisition Agreements under the Divestiture Agreement, and that is on terms that Aadi’s board of directors has determined in good faith (after consultation with its financial advisor and outside legal counsel) is (1) reasonably likely to be consummated in accordance with